pamidronate has been researched along with Bladder Cancer in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 65-year-old woman admitted for palliative care of metastatic renal/bladder carcinoma developed symptomatic hypocalcemia nine days following a single dose of pamidronate." | 7.69 | Symptomatic hypocalcemia after intravenous pamidronate. ( Bruera, E; McIntyre, E, 1996) |
| "A 65-year-old woman admitted for palliative care of metastatic renal/bladder carcinoma developed symptomatic hypocalcemia nine days following a single dose of pamidronate." | 3.69 | Symptomatic hypocalcemia after intravenous pamidronate. ( Bruera, E; McIntyre, E, 1996) |
| "In view of previous animal studies showing that pamidronate (Aredia) can cause renal damage, and human data indicating that pamidronate in doses of 60-90 mg is more effective in the control of tumor-induced hypercalcemia than when given at lower doses, we decided to investigate whether pamidronate 90 mg infused over 60 minutes at weekly intervals had any adverse effects on renal function in patients with bone metastases." | 2.67 | Intravenous pamidronate: infusion rate and safety. ( Coleman, T; Collinson, M; Ford, JM; Madsen, EL; Tyrrell, CJ, 1994) |
| "This osteolysis was evaluated by measuring the increased area of bone resorption in reduced opacity to radiograph and histologic study." | 1.28 | Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. ( Koiso, K; Miyagawa, I; Nemoto, R; Satou, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tyrrell, CJ | 1 |
| Collinson, M | 1 |
| Madsen, EL | 1 |
| Ford, JM | 1 |
| Coleman, T | 1 |
| McIntyre, E | 1 |
| Bruera, E | 1 |
| Nemoto, R | 2 |
| Satou, S | 1 |
| Miyagawa, I | 1 |
| Koiso, K | 2 |
| Nishijima, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pamidronate and Bladder Cancer
| Article | Year |
|---|---|
Intravenous pamidronate: infusion rate and safety.
Topics: Adult; Aged; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Ad | 1994 |
3 other studies available for pamidronate and Bladder Cancer
| Article | Year |
|---|---|
Symptomatic hypocalcemia after intravenous pamidronate.
Topics: Aged; Alberta; Carcinoma, Transitional Cell; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalc | 1996 |
Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Female; Mice; Mice, Inbred C3H; Necrosis; Neop | 1991 |
[Establishment of a model to evaluate inhibition of bone resorption induced by bladder tumor (MBT-2) in mice].
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Models, Animal; Female; Mice; Neop | 1990 |